<DOC>
	<DOCNO>NCT00089193</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood . Combining vaccine therapy sargramostim may cause strong immune response kill tumor cell . PURPOSE : This randomized phase II trial study vaccine therapy sargramostim see well work compare vaccine therapy alone treat patient stage II B , stage IIC , stage III , stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy With Without Sargramostim Treating Patients With Stage IIB , Stage IIC , Stage III , Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare immune response patient stage IIB-IV melanoma treat vaccination comprise multiple synthetic melanoma peptide Montanide ISA-51 v without sargramostim ( GM-CSF ) . - Compare immune response patient treat vaccination administer 1 v 2 site . OUTLINE : This randomize , open-label study . Patients randomize 1 4 treatment arm . - Arm I : Patients receive vaccination comprise multiple synthetic melanoma peptide Montanide ISA-51 1 injection site . - Arm II : Patients receive vaccination comprise multiple synthetic melanoma peptide Montanide ISA-51 2 injection site . - Arm III : Patients receive vaccination comprise multiple synthetic melanoma peptide , Montanide ISA-51 , sargramostim ( GM-CSF ) 1 injection site . - Arm IV : Patients receive vaccination comprise multiple synthetic melanoma peptide , Montanide ISA-51 , GM-CSF 2 injection site . In arm , treatment repeat weekly 6 week . Patients return booster vaccination week 12 , 26 , 39 , 52 . PROJECTED ACCRUAL : A maximum 124 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis melanoma Stage IIB , IIC , III , IV disease Must express HLAA1 , A2 , A3 No ocular melanoma PATIENT CHARACTERISTICS : Age 12 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 9 g/dL Hepatic Liver function test ≤ 2.5 time upper limit normal ( ULN ) Renal Creatinine ≤ 1.5 time ULN Cardiovascular No New York Heart Association class III IV heart disease Other Not pregnant nursing No malignancy within past 5 year except basal cell squamous cell skin cancer without brain metastasis , carcinoma situ breast , carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior immunotherapy More 4 week since prior growth factor More 4 week since prior allergy shot No prior vaccine therapy melanoma cancer peptide use study More 12 week since prior melanoma vaccine therapy* NOTE : *Prior melanoma vaccine allow patient disease progression administration vaccine Chemotherapy More 4 week since prior chemotherapy Endocrine therapy More 4 week since prior steroid Radiotherapy More 4 week since prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>